Asgard Therapeutics has announced the appointment of Prof. Dr. Wolfram Brugger as Chief Medical Officer, signaling a strategic move to advance their lead asset, AT-108, into Phase 1 clinical development. AT-108 represents a novel off-the-shelf immunotherapy that utilizes in vivo reprogramming to convert tumor cells into antigen-presenting cells, specifically conventional dendritic cells type 1 (cDC1). This transformative approach aims to elicit a personalized immune response against various cancers, leveraging the patient’s own immune system to target tumors more effectively.

The significance of AT-108 lies in its ability to reprogram cancer cells to present their own antigens, thus enhancing the immune system’s recognition and attack on tumors. The pre-clinical proof-of-concept data, which has been published in a high-impact journal, demonstrates the therapy’s potential to trigger robust cytotoxic T cell responses. Asgard is currently focused on completing IND-enabling studies and CMC activities to support the clinical development of this first-in-class therapy, which could have far-reaching implications for cancer treatment paradigms.

The appointment of Brugger, who brings extensive experience from leading clinical development programs at notable biotech firms, underscores Asgard’s commitment to ensuring a successful transition into clinical trials. His expertise in oncology and prior successes with CAR T therapies and monoclonal antibodies may accelerate the development timeline for AT-108. This shift not only enhances Asgard’s leadership capabilities but also positions the company to potentially redefine therapeutic strategies in cancer immunotherapy, paving the way for more effective, personalized treatment options for patients.

Source: globenewswire.com